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Distinct types of GABAergic interneurons target different subcellular domains of 29 
pyramidal cells, thereby shaping pyramidal cell activity patterns. Whether the 30 
presynaptic heterogeneity of GABAergic innervation is mirrored by specific 31 
postsynaptic factors is largely unexplored. Here we show that dystroglycan, a protein 32 
responsible for the majority of congenital muscular dystrophies when dysfunctional, 33 
has a function at postsynaptic sites restricted to a subset of GABAergic interneurons. 34 
Conditional deletion of Dag1, encoding dystroglycan, in pyramidal cells caused loss of 35 
CCK-positive basket cell terminals in hippocampus and neocortex. PV-positive basket 36 
cell terminals were unaffected in mutant mice, demonstrating interneuron subtype-37 
specific function of dystroglycan. Loss of dystroglycan in pyramidal cells had little 38 
influence on clustering of other GABAergic postsynaptic proteins and of 39 
glutamatergic synaptic proteins. CCK-positive terminals were not established at P21 in 40 
the absence of dystroglycan and were markedly reduced when dystroglycan was 41 
ablated in adult mice, suggesting a role for dystroglycan in both formation and 42 
maintenance of CCK-positive terminals. The necessity of neuronal dystroglycan for 43 
functional innervation by CCK-positive basket cell axon terminals was confirmed by 44 
reduced frequency of inhibitory events in pyramidal cells of dystroglycan-deficient 45 
mice and further corroborated by the inefficiency of carbachol to increase IPSC 46 
frequency in these cells. Finally, neurexin binding seems dispensable for dystroglycan 47 
function since knock-in mice expressing binding-deficient T190M dystroglycan 48 
displayed normal CCK-positive terminals. Taken together, we describe a novel 49 
function of dystroglycan in interneuron subtype-specific trans-synaptic signaling, 50 
revealing correlation of pre- and postsynaptic molecular diversity. 51 
 52 
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Significance statement 53 
Dystroglycan, an extracellular and transmembrane protein of the dystrophin glycoprotein 54 
complex, is at the center of molecular studies of muscular dystrophies. Although its synaptic 55 
distribution in cortical brain regions is long established, function of dystroglycan in the 56 
synapse remained obscure. Using mice that selectively lack neuronal dystroglycan, we 57 
provide evidence that a subset of GABAergic interneurons requires dystroglycan for 58 
formation and maintenance of axonal terminals on pyramidal cells. As such, dystroglycan is 59 
the first postsynaptic GABAergic protein for which an interneuron terminal-specific function 60 
could be shown. Our findings also offer a new perspective on the mechanisms that lead to 61 
intellectual disability in muscular dystrophies without associated brain malformations. 62 
Introduction 63 
GABAergic interneurons, which provide the main source of inhibitory drive in the adult 64 
mammalian brain, form several distinct classes according to morphological, molecular and 65 
functional criteria (Fishell and Rudy, 2011). This specialization allows interneurons to adapt 66 
to different demands of postsynaptic targets and thereby control membrane excitability in a 67 
spatially and temporally precise manner (Klausberger and Somogyi, 2008). Most interneuron 68 
classes innervate only a specific subcellular domain of target cells, for example the axon 69 
initial segment, the cell soma or dendritic regions. Synaptic transmission from different 70 
interneuron subtypes has thus fundamentally different impact on the activity of postsynaptic 71 
cells. It might be advantageous to account for this diversity of GABAergic innervation with 72 
postsynaptic specializations matching the specific properties and plasticity mechanisms of 73 
synaptic terminals they are contacted from. Indeed, the GABAergic postsynaptic density 74 
(PSD) is characterized by a large molecular heterogeneity (Tyagarajan and Fritschy, 2014). 75 
However, little is known about such subtype-specific postsynaptic GABAergic adaptations. 76 
Basket cells are GABAergic interneurons that specifically target the perisomatic region of 77 
principal neurons. In cerebral cortex and hippocampus, expression of parvalbumin (PV) or 78 
cholecystokinin (CCK) identifies basket cells as belonging to one of two non-overlapping 79 
groups (Freund and Katona, 2007). Although these two interneuron subtypes innervate the 80 
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same subcellular domain, they are distinguished by various traits (Bartos and Elgueta, 2012). 81 
Only CCK-positive basket cells express presynaptic cannabinoid receptors, enabling 82 
retrograde signaling of endocannabinoids to suppress GABA release. Different firing 83 
patterns, expression profiles and developmental origins further set the two subtypes apart. 84 
Therefore, it is conceivable that the two types of basket cells use different mechanisms for 85 
synapse formation and require a different set of postsynaptic proteins to exert their vastly 86 
different functions. 87 
Dystroglycan (DG) is the central component of the dystrophin glycoprotein complex (DGC). 88 
The extracellular α-DG and transmembrane β-DG, generated by proteolytic cleavage of a 89 
single gene product, bind the large cytoplasmic protein dystrophin, which in turn can interact 90 
with actin filaments. α-DG, through its glycosyl side chains, can bind to extracellular matrix 91 
components. The crucial role of the DGC in muscle tissue was revealed by mutations 92 
affecting DGC components that lead to muscular dystrophies (McNally and Pytel, 2007). The 93 
DGC, albeit differing slightly in its molecular composition, is also expressed in the central 94 
nervous system by glial cells and neurons (Waite et al., 2012). Developmental brain 95 
malformations and intellectual disability, observed frequently in muscular dystrophies caused 96 
by DGC dysfunction, testify to the importance of this complex for brain function. The finding 97 
that the DGC is present in pyramidal cells as large, mostly perisomatic clusters postsynaptic 98 
to GABAergic terminals spurred interest in the synaptic function of the DGC (Lidov et al., 99 
1990). Because reduced GABAAR immunoreactivity was found in a mouse model of 100 
Duchenne’s muscular dystrophy (DMD), a function for the DGC in clustering of PSD 101 
components was posited (Knuesel et al., 1999; Vaillend et al., 2010). Despite the selective 102 
DGC subcellular distribution, biochemical interaction with presynaptic neurexins and the 103 
obligatory association of DG with GABAergic presynaptic terminals in neuronal cultures, the 104 
role of the DGC in trans-synaptic signaling was never systematically assessed (Sugita et al., 105 
2001; Brunig et al., 2002). 106 
We hypothesized that the diversity of GABAergic PSD composition is functionally related to 107 
the heterogeneity of GABAergic innervation. Due to its restricted distribution and known role 108 
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as a transmembrane complex, DG seemed ideally suited to address this issue. Ablation of 109 
DG specifically in pyramidal neurons allowed us to study the synaptic function of the DGC 110 
without confounding deficits in neuronal migration associated with loss of DG in other 111 
tissues. Using this approach, we demonstrate that the neuronal DGC plays an essential role 112 
in trans-synaptic signaling necessary for formation and maintenance of functional axon 113 
terminals from CCK-positive basket cells. Since the neuronal circuits depending on this 114 
signaling have been shown to be involved in major cognitive functions, our findings open new 115 
avenues in identifying the causes of intellectual disability in muscular dystrophies. 116 
Materials and Methods 117 
Animals. All mice were bred on C57BL/6 background at the Laboratory Animal Service 118 
Center (Schlieren, Zurich, Switzerland) and kept in standard housing with food and water 119 
provided ad libitum. Mice harboring loxP sites in exon 2 of Dag1 were obtained from The 120 
Jackson Laboratory (Bar Harbor, ME). NEX-Cre transgenic mice were provided by Dr. 121 
Sandra Goebbels (Max-Planck-Institute of Experimental Medicine, Goettingen, Germany). 122 
Dag1 T190M knock-in mice were provided by Dr. Kevin P. Campbell (Howard Hughes 123 
Medical Institute, Iowa City, IA). Dag1 floxed mice were genotyped by PCR analysis using 124 
primers 5’-GGAGAGGATCAATCATGG-3’ and 5’-CAACTGCTGCATCTCTAC-3’. Genotyping 125 
of NEX-Cre transgenic mice was performed as described (Goebbels et al., 2006). To obtain 126 
DG cKO and control mice, NEX-Cretg/+ / Dag1loxP/+ mice were bred to NEX-Cre+/+ / 127 
Dag1loxP/loxP mice. All experiments were approved by the veterinary office of the Canton of 128 
Zurich. 129 
Western blotting. Adult DG cKO and control mice of both sexes were anaesthetized with 130 
pentobarbital (Nembutal; 50 mg/kg intraperitoneally) and sacrificed by decapitation. Cheek 131 
muscle was dissected on ice and transferred to lysis buffer (50 mM Tris (pH 7.6), 150 mM 132 
NaCl, 1% Triton X-100, Complete Mini Protease Inhibitor Cocktail [Roche, Rotkreuz, 133 
Switzerland]). Tissue was Dounce homogenized, sonicated and incubated on ice for 1h. 134 
Lysates were centrifuged at 50’000 RPM for 1h at 4 °C and supernatants were stored at -80 135 
°C. For anti-α-DG blots, glycosylated proteins were enriched by incubating lysates with wheat 136 
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germ agglutinin (WGA) agarose beads (Vector Labs, Burlingame, CA) at 4 °C overnight 137 
(ON). Proteins were eluted with 300 mM N-Acetyl-glucosamine and stored at -20 °C. 138 
Laemmli buffer was added to WGA-enriched and non-enriched lysates (for loading control) 139 
and samples were run on 8% tris-glycine polyacrylamide gels. Proteins were transferred to 140 
polyvinylidene fluoride (PVDF) membranes. Mouse anti-α-DG (11H6C4; Millipore; 1:1000) 141 
and rabbit anti-actin (Sigma; 1:5000) antibodies were incubated in tris-buffered saline with 142 
0.05% Tween 20 (TBST) including 5% Western Blocking Solution (Roche) ON at 4 °C. 143 
Membranes were washed 5 times in TBST. Horseradish peroxidase-coupled donkey 144 
secondary antibodies (1:20’000) were incubated for 1h at room temperature (RT) and 145 
membranes were washed again 5 times in TBST. SuperSignal West Pico Chemiluminescent 146 
Substrate (Thermo Fisher Scientific, Waltham, MA) was applied and membranes were 147 
developed on X-ray film (Fujifilm, Tokyo, Japan). 148 
Tissue preparation for immunohistochemistry. DG cKO and control mice of both sexes at the 149 
age of 8 to 12 weeks were anaesthetized by intraperitoneal pentobarbital injection 150 
(Nembutal; 50 mg/kg) and perfused transcardially with ice-cold oxygenated artificial 151 
cerebrospinal fluid (ACSF; pH 7.4) for 2 min, as described (Notter et al., 2014). Brains were 152 
immediately dissected and fixed in 4% paraformaldehyde (PFA) for 100 min on ice. After 153 
rinsing in phosphate-buffered saline (PBS), brains were incubated in 30% sucrose (in PBS) 154 
at 4 °C ON. 50 μm thick coronal sections were cut from frozen blocks using a sliding 155 
microtome (HM400; Microm, Walldorf, Germany) and stored at -20 °C in antifreeze solution. 156 
Tissue preparation from P21 mice followed the same protocol with the following 157 
modifications: Mice were perfused with 4% PFA (after brief perfusion with PBS to rinse 158 
blood) and brains were post-fixed for 3h. 159 
Immunohistochemistry. After rinsing once in PBS, sections were incubated in primary 160 
antibody solution (50 mM Tris, 150 mM NaCl, 0.2% Triton X-100, 2% normal goat serum 161 
(NGS), pH 7.4) with antibodies listed in Table 1. Primary antibodies were incubated at 4 °C 162 
ON, or for 3 days if DG or dystrophin was labelled. Sections were washed 3 times for 10 min 163 
in PBS and incubated in secondary antibody solution (50 mM Tris, 150 mM NaCl, 0.05% 164 
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Triton X-100, 2% NGS, pH 7.4) for 30 min at RT with secondary antibodies raised in goat. 165 
Antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 647 (Invitrogen, La Jolla, CA) were 166 
diluted 1:1000 whereas antibodies conjugated to Cy3 (Jackson ImmunoResearch, West 167 
Grove, PA) were diluted 1:500. Sections were washed 3 times for 10 min in PBS and 168 
mounted on gelatin-coated slides using Fluorescence Mounting Medium (Dako, Carpinteria, 169 
CA). 170 
Image analysis. Z-stack images (3 optical sections, 0.5 µm step size) were recorded of all 171 
specimens using confocal laser scanning microscopy (LSM 700, Carl Zeiss, Oberkochen, 172 
Germany). Images were taken using a 40x objective with a numerical aperture of 1.4 and 173 
had a pixel size of 112 x 112 nm2. To reduce variability, 3-4 sections were imaged per mouse 174 
and cluster density values were averaged from these sections. All imaging parameters were 175 
kept constant between genotypes. For cluster analysis, maximum intensity projections were 176 
created from z-stacks and analyzed using ImageJ (NIH, Bethesda, MD). Representative 177 
example images were processed with Imaris (Bitplane, Belfast, UK). 178 
Stereotactic injections. 8 to 10 weeks old mice transgenic for loxP in exon 2 of Dag1 were 179 
anaesthetized with isoflurane (Attane; Piramal, Mumbai, India). After mice were head-fixed 180 
on a stereotactic frame (David Kopf Instruments, Tujunga, CA), a small longitudinal incision 181 
was made under continuous administration of isoflurane to reveal the skull. Bregma was 182 
identified and the skull was perforated unilaterally using a surgical drill at the following 183 
coordinates relative to Bregma: x = -1.9 mm, y = 1.6 mm. A glass pipette filled with virus 184 
solution was inserted into the brain to z = 1.5 mm. A total of 1 μL virus solution was injected 185 
using an automated injection pump in increments of 70 nL over 10 min. The pipette was 186 
removed and the incision sutured. Mice were injected intraperitoneally with 1 mg/kg 187 
buprenorphine (Temgesic; Essex Chemicals, Lucerne, Switzerland) and placed on a warm 188 
pad for recovery before returning to the home cage. 189 
Virus. AAV8-CaMKIIa-mCherry-Cre (dot blot titer 4.7x1012 VG/mL) was purchased from the 190 
University of North Carolina Vector Core (Chapel Hill, NC). 191 
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Acute brain slice preparation. 5 to 6 weeks old DG cKO and control mice were briefly 192 
anaesthetized with isoflurane and decapitated. The brain was quickly removed and 193 
transferred to ice-cold solution containing 65 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 194 
mM NaHCO3, 7 mM MgCl2, 0.5 mM CaCl2, 25 mM glucose and 105 mM sucrose saturated 195 
with 95% O2 and 5% CO2. 350 μm-thick transverse slices containing the hippocampus were 196 
cut from the tissue block with a vibratome (Microm HM 650V, Thermo Scientific, Waltham, 197 
MA) and kept in oxygenated ACSF (315 mOsm) containing 125 mM NaCl, 2.5 mM KCl, 1.25 198 
mM NaH2PO4, 25 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2 and 25 mM glucose at 34 °C for 199 
25 min and then at room temperature until use. 200 
Electrophysiology and data analysis. For recording, individual slices were transferred to a 201 
recording chamber perfused with oxygenated ACSF solution (same as above) at a flow rate 202 
of 1 to 2 mL/min. Whole-cell recordings were made from hippocampal CA1 pyramidal 203 
neurons. Cells were first selected using oblique IR illumination with a BX51 microscope (40x 204 
water-immersion objective; Olympus, Tokyo, Japan). Subsequently, neurons were 205 
anatomically identified using a fluorescent dye (Alexa 488, 10 µM) included in the 206 
intracellular solution. The dye was excited with wLS broad-band LED illumination (488 nm) 207 
and images were acquired with Retiga R1 camera using Ocular software (Qimaging, Surrey, 208 
Canada). The cells were patched with borosilicate glass pipettes (2-5 MΩ) containing: 135 209 
mM KCl, 10 mM HEPES, 10 mM sodium phosphocreatine, 4 mM Mg-ATP, 0.3 mM Na-GTP, 210 
pH 7.3 with KOH. Recordings were performed using Multiclamp 700B amplifier and data 211 
were acquired with a Digidata 1550A 16-bit board (all from Molecular Devices, Sunnyvale, 212 
CA). All experiments were performed at room temperature. Spontaneous inhibitory 213 
postsynaptic currents (sIPSC) were recorded from CA1 pyramidal cells clamped at a 214 
membrane voltage of -70 mV in the presence of 10 μM NBQX to block excitatory 215 
transmission. Recordings with unstable baseline or greater than -400 pA were rejected. 216 
Currents were filtered off-line using a Butterworth low-pass filter (2 kHz) and analyzed in 1 or 217 
2 min bins using the Mini-Analysis Program 6.0.7 (Synaptosoft, Decatur, GA). For 218 
pharmacology, baseline was analyzed 2 minutes before the application of carbachol (CCh, 219 
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10 μM). To study the effect of CCh, 1-2 min bins were analyzed at least 8 minutes following 220 
the arrival of CCh into the bath. Recordings with leak increasing more than 100 pA and 221 
access resistance changing more than 30% between the beginning and the end of the 222 
recording were discarded. At least 100 events were analyzed for any condition in any 223 
experiment. Events were identified as sIPSC by setting the event detection threshold at least 224 
2-fold the baseline noise level and by checking that events had (i) rise times faster than the 225 
decay time, (ii) rise times greater than 0.5 ms and (iii) decay times greater than 1.5 ms. 226 
Events not fitting the above parameters were rejected. Event amplitudes, inter-event 227 
intervals, rise and decay times were first averaged within each experiment and regrouped by 228 
condition. The frequencies were calculated from the inter-event intervals and the resulting 229 
means were averaged between experiments. Single cell properties (access resistance, 230 
membrane capacitance, etc.) were analyzed with Clampfit 10.5 (Axon instruments, Union 231 
City, CA). Graphs were done using Igor 6.37 software (Wavemetrics, Tigard, OR) and 232 
Illustrator 15.1.0 (Adobe, San José, CA). 233 
Results 234 
Use of NEX-Cre driver line for pyramidal cell-specific DG ablation 235 
To study the role of neuronal DGC in the brain without gross morphological alterations, it is 236 
necessary to target DG in neurons but spare glial DG. For this reason, mice harboring loxP 237 
sites in Dag1 were crossed to the NEX-Cre driver line, which exhibits an exclusively neuronal 238 
Cre recombinase expression pattern (Goebbels et al., 2006; Satz et al., 2010). In 239 
hippocampus and neocortex, NEX promoter-mediated Cre expression is restricted to 240 
pyramidal cells, the cell type displaying most prominent DG expression in the forebrain. DG 241 
conditional knockout mice (cKO; NEX-CreTg/+, Dag1loxP/loxP) showed reduced size compared 242 
to control mice (NEX-CreTg/+, Dag1loxP/+; Figure 1A). The smaller size was reflected in 243 
reduced body and brain weight (Figure 1B and C; 25.3 ± 1.0 g [mean ± SEM] versus 18.7 ± 244 
1.0 g, t28=4.670, p<0.001 and 473.1 ± 5.4 mg versus 436.4 ± 6.5 mg, t28=4.381, p<0.001, 245 
unpaired t-tests). Although cKO mice were born in Mendelian proportions, in adulthood less 246 
than the expected 25% cKO were observed due to higher lethality of cKO mice (Figure 1D). 247 
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To exclude a contribution of muscular dystrophy to this phenotype because of Cre leakage in 248 
muscle cells, α-DG levels were examined by Western blotting of WGA-enriched muscle 249 
proteins. cKO mice showed similar levels of muscle α-DG as control mice (Figure 1E). As 250 
reported before, DG cKO mice retained proper lamination of hippocampus (Figure 1F) and 251 
neocortex (Figure 1G) according to NeuN and DAPI labeling (Satz et al., 2010). Cre 252 
expression was restricted to pyramidal cells in hippocampus and neocortex and was not 253 
detected in dentate gyrus granule cells of adult mice (Figure 1F and G) (Goebbels et al., 254 
2006). 255 
Efficiency and specificity of DG ablation was examined immunohistochemically in relevant 256 
brain regions. α-DG, β-DG and dystrophin can be detected immunohistochemically in large 257 
perisomatic clusters in CA1 pyramidal cells (Figure 2A) (Lidov et al., 1990; Knuesel et al., 258 
1999). This characteristic immunolabeling was absent in DG cKO mice for DG and to the 259 
same extent for dystrophin, showing that dystrophin needs DG for synaptic clustering in vivo. 260 
In neocortex, perisomatic distribution of α-DG, β-DG and dystrophin was replaced by diffuse 261 
unspecific staining in neuropil in DG cKO mice (Figure 2B). Astrocyte endfeet are labeled 262 
prominently by antibodies to β-DG and dystrophin and this labeling was preserved in DG 263 
cKO mice, as expected from neuron-specific Cre expression (asterisks in Figure 2A and B). 264 
α-DG immunolabeling in dentate gyrus granule cells showed the same clustered distribution 265 
in both genotypes (Figure 2C). The transient NEX promoter activity in these cells during early 266 
postnatal development might not be sufficient to achieve recombination (Goebbels et al., 267 
2006). Alternatively, loss of DG during early development might be of little consequence in 268 
adulthood because of DG expression by granule cells that were born later. To further 269 
demonstrate specificity of NEX-induced DG ablation, striatum was selected as a control 270 
region. As expected, the characteristic sparse α-DG labeling persisted in striatum of DG cKO 271 
mice (Figure 2D). 272 
Loss of neuronal DG results in minor alterations in GABAergic PSD protein clustering 273 
Dependence of GABAergic postsynaptic density (PSD) proteins on the DGC for synaptic 274 
clustering was suggested because of the subcellular localization of the DGC, its molecular 275 
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interactions and because a reduction in GABAAR clustering was observed in mice lacking 276 
full-length dystrophin (Knuesel et al., 1999; Sumita et al., 2007; Waite et al., 2012). However, 277 
requirement of DG for clustering of GABAergic postsynaptic proteins was never 278 
systematically tested in vivo. We hypothesized that loss of neuronal DG affects neuroligin 2 279 
(NL2) clustering, which might be important for clustering of GABAARs at perisomatic 280 
synapses through its interaction with gephyrin (Poulopoulos et al., 2009; Panzanelli et al., 281 
2011). DG cKO and control mice were analyzed for changes in clustering of these markers in 282 
CA1 pyramidal layer. As previously reported (Knuesel et al., 1999; Brunig et al., 2002; Levi et 283 
al., 2002), extensive colocalization of α-DG and dystrophin was observed with GABAergic 284 
markers, with a minority of DGC clusters showing no colocalization (Figure 3A and B; 285 
arrowheads and arrows, respectively). Visual examination of GABAergic markers revealed 286 
no obvious differences between genotypes (Figure 3A-C). However, quantification of cluster 287 
density and size showed a significant decrease of GABAAR α1 subunit size in cKO 288 
accompanied by an increase of GABAAR α2 subunit density (Figure 3D and F). No changes 289 
were observed in GABAAR γ2 subunit and gephyrin clustering (Figure 3E and H), indicating 290 
that total synaptic GABAAR content might be unchanged whereas α subunit composition is 291 
altered by loss of DG. Surprisingly, NL2 clustering was barely affected in cKO mice, showing 292 
no difference in density and only a slight but significant reduction in cluster size (Figure 3G). 293 
Neuronal DGC is also dispensable for normal colocalization of GABAAR γ2 subunit with 294 
gephyrin and of α1 subunit with NL2 (Figure 3I). Furthermore, dystrophin was suggested to 295 
be important for anchoring synArfGEF at GABAergic PSDs (Fukaya et al., 2011). Although 296 
dystrophin clustering is lost in DG cKO mice, synArfGEF distribution remained almost 297 
unchanged in CA1 pyramidal layer of cKO mice (Figure 3J). 298 
Neuronal DG ablation leads to selective loss of markers of CCK-positive basket cell 299 
terminals 300 
Many binding partners of α-DG have been identified, among them the presynaptic neurexins 301 
(Sugita et al., 2001). Taken together with the observation that DG is always apposed to 302 
GABAergic presynaptic terminals in primary neuronal culture, a trans-synaptic function for 303 
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DG seemed probable (Brunig et al., 2002). We therefore probed DG cKO and control brains 304 
tissue with antibodies to presynaptic GABAergic markers. Perisomatic GABAergic terminals 305 
can be attributed to parvalbumin (PV)- or cholecystokinin (CCK)-positive interneurons, which 306 
are labeled by PV / synaptotagmin 2 (Syt2) and CCK8 / VGluT3 / cannabinoid receptor 1 307 
(CB1), respectively. We found that markers for presynaptic terminals from CCK-positive 308 
interneurons were virtually absent in CA1 pyramidal layer of DG cKO mice (Figure 4A-D, G, I 309 
and K). Still, like in control mice, CCK-positive cell somata were occasionally observed in 310 
cKO CA1 pyramidal layer, and these were often covered with VGluT3-positive boutons 311 
(arrowheads in Figure 4A). Syt2 and PV immunolabeling were still present in typical punctate 312 
distribution in the pyramidal layer of cKO mice (Figure 4A-D, H and J), demonstrating specific 313 
requirement of DG for formation of presynaptic terminals from CCK-positive interneurons. 314 
Preferential apposition of DG to CCK-positive interneuron terminals might be expected from 315 
this finding. However, apposition of DG to VGluT3 as well as to PV suggests no such 316 
distinction, at least at the resolution of conventional confocal laser scanning microscopy 317 
(arrowheads in C). Still, as percentage of presynaptic immunofluorescence apposed to DG, 318 
VGluT3 showed more complete overlap with DG, indicating PV apposition to DG might be 319 
caused by mere abundance of PV immunofluorescence in the pyramidal layer (data not 320 
shown). Loss of CCK-positive interneuron terminals extended from CA3 to CA1 (Figure 4E). 321 
Surprisingly, no corresponding reduction in VGAT puncta was observed (Figure 4F). 322 
Because the DGC is prominently expressed by pyramidal cells in the neocortex, it seemed 323 
likely that CCK-positive interneuron terminals in neocortex are also compromised by loss of 324 
neuronal DG. Indeed, CCK8 and CB1 immunolabeling was strongly reduced in primary 325 
somatosensory cortex (S1) of DG cKO mice whereas PV staining was unchanged (apart 326 
from a minute difference in size; Figure 5). VGluT3 puncta density was not decreased in 327 
neocortex of DG cKO mice, in agreement with histological studies showing VGluT3 is 328 
present mostly in serotonergic fibers in this brain area (Figure 5B and G)(Schafer et al., 329 
2002). As in hippocampus, reduction of CCK-positive terminals was not paralleled by a 330 
decrease of VGAT puncta (Figure 5A and E). Markers for CCK-positive terminals were 331 
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reduced uniformly across all cortical layers and in all regions of the neocortex which were 332 
examined (Figure 5D). 333 
Satz et al. (2010) have reported blunted long-term potentiation in CA1 pyramidal cells of 334 
mice with NEX-Cre-mediated DG ablation. To exclude that loss of CCK-positive interneuron 335 
terminals represents compensatory changes to large glutamatergic alterations, glutamatergic 336 
markers were examined as a proxy for integrity of glutamatergic synapses (Figure 6). 337 
Clustering of the postsynaptic glutamatergic markers PSD-95 and bassoon did not differ 338 
significantly between genotypes (Figure 6A and B) and neither did VGluT1 immunolabeling 339 
(Figure 6C). Furthermore, the portion of PSD-95 clusters apposed to VGluT1 was similar in 340 
both genotypes (Figure 6D). 341 
Formation and maintenance of CCK-positive basket cell terminals require neuronal DG 342 
DG expressed by pyramidal cells might have a function in synapse formation or in guidance 343 
of a subset of axons, similar to its role in the spinal cord (Wright et al., 2012). Alternatively, a 344 
function in maintenance of synapses through continuous trans-synaptic signaling is 345 
conceivable. If neuronal DG is crucial for synapse formation of CCK-positive terminals, these 346 
boutons should be reduced to the same degree as in adults at a time point right after initial 347 
synaptogenesis. Following this reasoning, we examined CCK-positive terminals of 21-day-348 
old DG cKO and control mice in CA1 pyramidal layer. Indeed, VGluT3 puncta were largely 349 
missing also at this stage of development whereas immunostaining of PV-positive terminals 350 
was not significantly different between genotypes (Figure 7). 351 
Although this finding indicates that synapse formation of functional CCK-positive terminals 352 
depends on DG, it does not rule out a role for DG in maintaining already formed connections. 353 
In order to assess this putative function of DG in synapse maintenance, we ablated DG long 354 
after developmental synapse formation, by viral delivery of Cre to adult mice carrying one or 355 
both floxed Dag1 alleles. AAV8-CaMKII-mCherry-Cre was stereotactically injected 356 
unilaterally into the CA1 region and mice sacrificed at 14, 28, 42 or 84 days post injection 357 
(dpi; Figure 8A and C). At 14 dpi, Cre as well as mCherry fluorescence were clearly visible 358 
(Figure 8B). Loss of β-DG staining at 28 dpi in homozygously floxed mice indicated efficient 359 
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recombination of loxP sites (Figure 8D). In heterozygously floxed mice only a moderate 360 
reduction of β-DG labeling was observed, suggesting one wildtype allele is sufficient to 361 
sustain the bulk of DG expression. Because dystrophin immunostaining revealed a reduction 362 
that mirrored β-DG, and in addition showed lower background, dystrophin was used to 363 
assess DGC loss at subsequent time points (Figure 8E-G). Examination of VGluT3-positive 364 
terminals at 28 dpi in Cre-expressing regions of CA1 pyramidal layer revealed a moderate 365 
but significant reduction of VGluT3 puncta density and size in homozygously floxed mice 366 
compared to contralateral side as well as compared to the ipsilateral side of heterozygously 367 
floxed mice (Figure 8H). VGluT3-positive terminals in heterozygous mice were not affected. 368 
Compromised VGluT3 immunolabeling was also found at later time points in homozygous 369 
mice, and the effect became more prominent with increased time after injection (Figure 8I 370 
and J). Together, these results provide strong evidence for a role of DG both in synapse 371 
formation and in retrograde trans-synaptic signaling for maintenance of CCK-positive 372 
terminals. 373 
Absence of CCK-positive basket cell terminals due to DG ablation impacts pyramidal 374 
cell inhibitory input and response to cholinergic activation 375 
If axon terminals from CCK-positive basket cells are indeed lost in DG ablated mice, this 376 
should be reflected by functional changes of pyramidal cell inhibitory input. To test this 377 
hypothesis, acute slices were prepared from adult DG cKO and control brains and used for 378 
patch-clamp electrophysiological recordings from morphologically identified CA1 pyramidal 379 
cells (Figure 9). With inhibitors of glutamatergic transmission present in the bath, occurrence 380 
of spontaneous inhibitory postsynaptic currents (sIPSCs) was probed in both genotypes. As 381 
anticipated from immunohistological changes, sIPSC frequency in DG cKO was reduced to 382 
about half of that in control slices (Figure 9; 8.71 ± 1.52 Hz versus 4.46 ± 0.90 Hz, t26=2.214, 383 
p=0.036, unpaired t-test). Furthermore, DG cKO pyramidal cells were marked by a 384 
significantly smaller sIPSC amplitude than that of control cells (61.49 ± 7.90 pA versus 39.18 385 
± 2.39 pA, t26=2.374, p=0.025, unpaired t-test). No significant differences were found 386 
between genotypes in sIPSC rise and decay times (rise time 1.73 ± 0.09 ms versus 1.63 ± 387 
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0.12 ms, t26=0.664, p=0.512, unpaired t-test; decay time 14.84 ± 0.64 ms versus 14.21 ± 0.53 388 
ms, t26=0.717, p=0.480, unpaired t-test). 389 
The differences observed in baseline sIPSCs could be due to a general reduction of 390 
inhibitory transmission instead of interneuron subtype-specific loss of terminals. In order to 391 
gain insight into the origin of reduced inhibitory transmission in DG cKO pyramidal cells, we 392 
examined the effect of the acetylcholine receptor agonist carbachol on inhibitory currents. In 393 
slices, carbachol exposure leads to an increase of perisomatic inhibitory transmission in 394 
pyramidal cells, which is mediated by direct excitation of CCK-positive interneurons (Nagode 395 
et al., 2014). Given that CB1 receptor-containing terminals are required for increased 396 
inhibitory transmission after application of carbachol, this effect should be absent in DG cKO 397 
mice, if CCK-positive basket terminals are indeed non-functional in these mice. Carbachol 398 
was bath-applied to DG cKO and control acute slices from which sIPSCs were recorded in 399 
CA1 pyramidal cells. In control slices, carbachol led to a robust increase in sIPSC frequency 400 
within minutes after application (Figure 10A-C; frequency: 6.15 ± 1.45 Hz versus 10.53 ± 401 
2.47 Hz, t7=3.522, p=0.010; amplitude: 63.36 ± 8.84 pA versus 70.35 ± 12.59 pA, t7=0.943, 402 
p=0.377; paired t-tests). However, no statistically significant effect of carbachol was observed 403 
in DG cKO pyramidal cells (Figure 10D-F; frequency: 3.45 ± 0.75 Hz versus 4.47 ± 1.56 Hz, 404 
t6=0.797, p=0.456; amplitude: 45.70 ± 4.17 pA versus 53.03 ± 5.00 pA, t6=1.239, p=0.262; 405 
paired t-tests). Together with the results from baseline recordings and immunohistochemical 406 
analysis, these findings strongly argue that functional connectivity between CCK-containing 407 
basket cells and pyramidal cells is lost in DG-ablated mice. 408 
Persistence of CCK-positive terminals in DG T190M knock-in mice suggests trans-409 
synaptic DG function is independent of neurexin binding 410 
The intriguing finding that DG is required for formation and maintenance of CCK-positive 411 
terminals calls for an assessment of the clinical significance of this observation. In a 412 
subgroup of dystroglycanopathies, intellectual disability, although severe, is not accompanied 413 
by neuronal migration deficits (Godfrey et al., 2007). Dag1 T190M knock-in mice are a model 414 
of one such form of dystroglycanopathy and resemble the symptoms found in patients with 415 
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the corresponding mutation (Dincer et al., 2003; Hara et al., 2011). Interestingly, this 416 
mutation abolishes binding of DG to neurexin, a putative presynaptic DG binding partner. We 417 
compared markers of CCK-positive terminals in CA1 pyramidal layer of homozygous Dag1 418 
T190M mice to wildtype mice (Figure 11). Surprisingly, both VGluT3 and CB1 puncta were 419 
indistinguishable between Dag1 T190M and wildtype mice. Weaker and more diffuse labeling 420 
in Dag1 T190M mice using the α-DG glycosylation-specific antibody 11H6 confirmed that this 421 
mutation affects glycosylation of neuronal DG (Figure 11B). Apposition of β-DG to PV or 422 
VGluT3-positive terminals was not changed by T190M mutation (Figure 11E). Therefore, DG 423 
function for CCK-positive terminals is likely neurexin-independent, which suggests a novel 424 
presynaptic receptor might be involved in this trans-synaptic connection. 425 
Discussion 426 
Our experiments have yielded five main findings about the synaptic function of DG. Ablation 427 
of neuronal DG, which also hindered synaptic clustering of dystrophin, led only to minor 428 
changes in clustering of GABAergic PSD proteins. These alterations might reflect 429 
compensatory changes to the massive presynaptic defects found in DG-deficient mice. 430 
Importantly, DG synaptic function is interneuron subtype-specific since loss of synaptic 431 
markers was restricted to CCK-expressing basket cell terminals. Formation and maintenance 432 
of these synapses required neuronal DG, indicating that trans-synaptic signaling is important 433 
both at the time of developmental synaptogenesis and continuously during adulthood. 434 
Function of CCK-positive basket cell terminals was likely compromised along with specific 435 
marker expression, since loss of DG resulted in a reduced baseline spontaneous inhibitory 436 
activity in pyramidal cells that could not be increased by carbachol. Finally, post-437 
phosphorylation glycosylation of DG is not necessary for CCK-positive synapse formation 438 
because Dag1 T190M knock-in mice showed normal CCK-positive terminals, suggesting that 439 
presynaptic receptors other than neurexins might be involved in DG trans-synaptic function. 440 
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Postsynaptic GABAergic alterations ascribed to DGC deficits may be secondary to 441 
innervation defects 442 
Ablation of DG in primary hippocampal culture has revealed that DG is not necessary for 443 
GABAergic synapse formation and for clustering of main GABAergic PSD proteins, including 444 
GABAARs (Levi et al., 2002). Yet, involvement of the DGC in clustering of GABAergic 445 
postsynaptic proteins was supported by several lines of evidence. Mdx mice, used as a DMD 446 
model because of their lack of full-length dystrophin, were shown to have reduced GABAAR 447 
(but not gephyrin) clustering in the hippocampus CA1 region (Knuesel et al., 1999). 448 
Overexpression of a shorter dystrophin construct in vivo rescued the decrease of GABAAR 449 
cluster density and size, adding to the notion that dystrophin loss directly caused GABAAR 450 
clustering defects (Vaillend et al., 2010). Neuroligin 2 (NL2) was shown to biochemically 451 
interact with dystrophin over the intracellular synaptic scaffolding molecule S-SCAM (Sumita 452 
et al., 2007). Furthermore, a functional connection between the DGC and NL2 is suggested 453 
by the observation that in GABAAR α2 subunit KO mice NL2 clustering is only compromised 454 
in dendritic but not in perisomatic areas (Panzanelli et al., 2011). The modest increase in 455 
GABAAR α2 subunit density and decrease in GABAAR α1 subunit size found in the present 456 
study does not correspond to the findings in mdx mice, in which both subunits cluster less 457 
efficiently than in wildtype mice (Knuesel et al., 1999; Vaillend et al., 2010). Rather, these 458 
alterations might reflect a subunit composition change because GABAAR γ2 subunit clusters 459 
were not affected by ablation of DG (except for a minute reduction in cluster size, which 460 
might be a reflection of reduced GABAAR α1 subunit cluster size). The finding that gephyrin 461 
clustering was unchanged in DG cKO mice further supports the conclusion that overall 462 
clustering of synaptic GABAAR subunits was not influenced by neuronal DG loss. The 463 
discrepancy between our results and published data from mdx mice might be explained by 464 
different roles of dystrophin isoforms at the GABAergic PSD. Short dystrophin isoforms still 465 
present in the mdx model might, by binding to DG, cause the reduction in synaptic GABAAR 466 
clustering. It is worth noting that the α2 subunit of GABAARs, which is localized preferentially 467 
at CCK-positive synapses (Nyiri et al., 2001), does not require the DGC or CCK-positive 468 
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terminals for clustering. The DGC is thus likely involved in targeting the α2 subunit to 469 
synapses apposed to CCK-positive terminals but clustering mechanisms seem to be DGC-470 
independent. NL2 clustering was intact in DG cKO mice, apart from a slight decrease in 471 
cluster size. Therefore, the notion of the DGC as an obligatory stabilizer of postsynaptic NL2 472 
clustering by mutual interaction with S-SCAM does not hold. Similarly, a role for the DGC in 473 
clustering the dystrophin-interacting protein synArfGEF at GABAergic synapses was 474 
suggested (Fukaya et al., 2011). Not excluding a contribution of the DGC to synArfGEF 475 
function by clustering additional signaling proteins, synArfGEF does not rely on the DGC to 476 
form clustered, presumably synaptic structures. 477 
In the light of the dramatic changes in GABAergic innervation due to DG loss, an indirect 478 
presynaptic contribution to reduced postsynaptic clustering in dystrophin-deficient models 479 
should be considered. This hypothesis is supported also by the finding of reduced CCK-480 
positive basket cell markers in mdx mice, suggesting that dystrophin plays part in trans-481 
synaptic signaling (Krasowska et al., 2014). The role of dystrophin in clustering signaling 482 
proteins at CCK-positive terminals is still unexplored, but might include retrograde signaling 483 
by nitric oxide synthase. Resolution of conventional confocal laser scanning microscopy is 484 
not sufficient to conclusively answer whether the DGC is restricted to synapses from CCK-485 
positive basket cells. Although apposition of DG to PV- and CCK-positive terminals was 486 
found with approximately equal frequency (Figure 11E), the percentage of CCK-positive 487 
terminals apposed to DG was higher than that of PV-positive terminals (data not shown; 488 
Figure 4C and 7A). Therefore, it seems likely that the DGC localizes preferentially 489 
postsynaptic to CCK-positive terminals to regulate synapse formation and function. 490 
Basket cell type specificity of DG function implies specificity of trans-synaptic 491 
interaction with presynaptic binding partner 492 
The selective dependence of the CCK-containing subtype of basket cells on neuronal DG for 493 
innervating target cells is a major finding of our study and has far-reaching implications. The 494 
DGC indeed acts as a trans-synaptic complex in central synapses, suggesting that 495 
presynaptic, rather than extracellular binding partners, enable DGC function in this context. 496 
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Any such presynaptic adhesion molecule would have to be specifically localized at CCK-497 
positive terminals. Interestingly, differential splicing of neurexins in PV- and CCK-expressing 498 
basket cells was recently reported (Fuccillo et al., 2015). Transcripts lacking neurexin1α 499 
alternative splice inserts 2 and 4, which prevent α-DG binding to LSM domains 2 and 6, 500 
respectively, were only found in CCK-positive basket cells (Sugita et al., 2001; Reissner et 501 
al., 2014; Fuccillo et al., 2015). This neurexin isoform-specificity of basket cell subtypes 502 
would provide a mechanism for selective dependence of CCK-positive basket terminals on 503 
DG. However, we found terminals from CCK-positive basket cells to be intact in Dag1 T190M 504 
knock-in mice. DG containing the T190M mutation was found to lose neurexin binding 505 
capacity (Hara et al., 2011). This finding thus suggests that a novel presynaptic DG binding 506 
partner might be specifically localized at CCK-positive terminals. But because the diversity of 507 
neurexin isoforms was not considered in DG T190M binding assays, the possibility of a 508 
specific neurexin-DG trans-synaptic complex at CCK-positive terminals remains. 509 
Continuous trans-synaptic signaling required for maintenance of CCK-positive 510 
terminals might reflect novel plasticity mechanism 511 
Stopping trans-synaptic signaling mediated by the DGC by ablating DG in adulthood led to a 512 
decrease of CCK-positive terminals within weeks. This unexpected result implies that DG 513 
function goes beyond a potential role in validating newly formed synapses from CCK-positive 514 
basket cells. In addition to clustering signaling molecules at these synapses, our findings 515 
open the possibility that the DGC, by forming a trans-synaptic complex, is a direct target to 516 
regulate abundance of CCK-positive terminals. β-DG is a substrate of MMP-9 in a neuronal 517 
activity-dependent manner (Yamada et al., 2001; Kaczmarek et al., 2002; Michaluk et al., 518 
2007). Cleavage of DG might therefore represent a physiological interneuron subtype-519 
specific plasticity mechanism. In striking agreement with this hypothesis, CCK-positive 520 
terminals are selectively lost in a model of temporal lobe epilepsy (Wyeth et al., 2010). 521 
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Decreased inhibitory input to pyramidal cells in DG-ablated cells confirms functional 522 
significance of DG signaling for CCK-positive terminals 523 
The possibility that loss of CCK-specific markers in DG cKO mice is only due to inability of 524 
terminals to differentiate was ruled out by the finding that DG-ablated pyramidal cells receive 525 
reduced inhibitory drive. Along with sIPSC frequency, amplitude was markedly reduced, 526 
possibly reflecting mistargeting of GABAARs in the absence of the DGC. Genesis of 527 
carbachol-induced increase of inhibitory currents is not fully understood but involves Gad2-528 
positive rather than PV-positive interneurons in the CA1 region (Nagode et al., 2014). Since 529 
the group of Gad2-expressing interneurons includes CCK-positive basket cells and 530 
carbachol-induced currents are sensitive to depolarization-induced suppression of inhibition, 531 
our results add to the notion that CCK-positive basket cells play a crucial role in carbachol-532 
induced activity. Activity patterns elicited by carbachol correlate with behaviorally relevant 533 
theta oscillations. Mechanisms of theta oscillation generation should thus be considered in 534 
future investigations of the etiology of intellectual disability associated with muscular 535 
dystrophies. 536 
Conclusions 537 
Our investigation of the role of neuronal DG in GABAergic synapses has revealed a 538 
surprising interneuron type-specific function of DG in trans-synaptic signaling. It has shown 539 
that GABAergic postsynaptic diversity is functionally related to interneuron subtype 540 
heterogeneity and supports the emerging notion of a cell type-specific molecular code of 541 
synapse formation. Future studies will have to further characterize signaling and plasticity 542 
enabled by the DGC and delineate its behavioral consequences. Taking the interneuron-543 
specific role of DG into consideration will help elucidate the mechanisms underlying 544 
intellectual disability observed in muscular dystrophies without developmental brain 545 
malformations. 546 
References 547 
Bartos M, Elgueta C (2012) Functional characteristics of parvalbumin- and cholecystokinin-548 
expressing basket cells. J Physiol 590:669-681. 549 
21 
 
Brunig I, Suter A, Knuesel I, Luscher B, Fritschy JM (2002) GABAergic terminals are required 550 
for postsynaptic clustering of dystrophin but not of GABA(A) receptors and gephyrin. J 551 
Neurosci 22:4805-4813. 552 
Dincer P, Balci B, Yuva Y, Talim B, Brockington M, Dincel D, Torelli S, Brown S, Kale G, 553 
Haliloglu G, Gerceker FO, Atalay RC, Yakicier C, Longman C, Muntoni F, Topaloglu H 554 
(2003) A novel form of recessive limb girdle muscular dystrophy with mental retardation and 555 
abnormal expression of alpha-dystroglycan. Neuromuscul Disord 13:771-778. 556 
Fishell G, Rudy B (2011) Mechanisms of inhibition within the telencephalon: "where the wild 557 
things are". Annu Rev Neurosci 34:535-567. 558 
Freund TF, Katona I (2007) Perisomatic inhibition. Neuron 56:33-42. 559 
Fritschy JM, Mohler H (1995) GABAA-receptor heterogeneity in the adult rat brain: 560 
differential regional and cellular distribution of seven major subunits. J Comp Neurol 561 
359:154-194. 562 
Fuccillo MV, Foldy C, Gokce O, Rothwell PE, Sun GL, Malenka RC, Sudhof TC (2015) 563 
Single-Cell mRNA Profiling Reveals Cell-Type-Specific Expression of Neurexin Isoforms. 564 
Neuron 87:326-340. 565 
Fukaya M, Kamata A, Hara Y, Tamaki H, Katsumata O, Ito N, Takeda S, Hata Y, Suzuki T, 566 
Watanabe M, Harvey RJ, Sakagami H (2011) SynArfGEF is a guanine nucleotide exchange 567 
factor for Arf6 and localizes preferentially at post-synaptic specializations of inhibitory 568 
synapses. J Neurochem 116:1122-1137. 569 
Godfrey C et al. (2007) Refining genotype phenotype correlations in muscular dystrophies 570 
with defective glycosylation of dystroglycan. Brain 130:2725-2735. 571 
Goebbels S, Bormuth I, Bode U, Hermanson O, Schwab MH, Nave KA (2006) Genetic 572 
targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice. Genesis 573 
44:611-621. 574 
Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, Kanagawa M, Beltran-Valero de Bernabe D, 575 
Gundesli H, Willer T, Satz JS, Crawford RW, Burden SJ, Kunz S, Oldstone MB, Accardi A, 576 
22 
 
Talim B, Muntoni F, Topaloglu H, Dincer P, Campbell KP (2011) A dystroglycan mutation 577 
associated with limb-girdle muscular dystrophy. N Engl J Med 364:939-946. 578 
Kaczmarek L, Lapinska-Dzwonek J, Szymczak S (2002) Matrix metalloproteinases in the 579 
adult brain physiology: a link between c-Fos, AP-1 and remodeling of neuronal connections? 580 
Embo J 21:6643-6648. 581 
Klausberger T, Somogyi P (2008) Neuronal diversity and temporal dynamics: the unity of 582 
hippocampal circuit operations. Science 321:53-57. 583 
Knuesel I, Mastrocola M, Zuellig RA, Bornhauser B, Schaub MC, Fritschy JM (1999) Short 584 
communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin 585 
(mdx mice). Eur J Neurosci 11:4457-4462. 586 
Krasowska E, Zablocki K, Gorecki DC, Swinny JD (2014) Aberrant location of inhibitory 587 
synaptic marker proteins in the hippocampus of dystrophin-deficient mice: implications for 588 
cognitive impairment in duchenne muscular dystrophy. PLoS One 9:e108364. 589 
Levi S, Grady RM, Henry MD, Campbell KP, Sanes JR, Craig AM (2002) Dystroglycan is 590 
selectively associated with inhibitory GABAergic synapses but is dispensable for their 591 
differentiation. J Neurosci 22:4274-4285. 592 
Lidov HG, Byers TJ, Watkins SC, Kunkel LM (1990) Localization of dystrophin to 593 
postsynaptic regions of central nervous system cortical neurons. Nature 348:725-728. 594 
McNally EM, Pytel P (2007) Muscle diseases: the muscular dystrophies. Annu Rev Pathol 595 
2:87-109. 596 
Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, Gorecki 597 
DC, Ottersen OP, Kaczmarek L (2007) Beta-dystroglycan as a target for MMP-9, in response 598 
to enhanced neuronal activity. J Biol Chem 282:16036-16041. 599 
Nagode DA, Tang AH, Yang K, Alger BE (2014) Optogenetic identification of an intrinsic 600 
cholinergically driven inhibitory oscillator sensitive to cannabinoids and opioids in 601 
hippocampal CA1. J Physiol 592:103-123. 602 
23 
 
Notter T, Panzanelli P, Pfister S, Mircsof D, Fritschy JM (2014) A protocol for concurrent 603 
high-quality immunohistochemical and biochemical analyses in adult mouse central nervous 604 
system. Eur J Neurosci 39:165-175. 605 
Nyiri G, Freund TF, Somogyi P (2001) Input-dependent synaptic targeting of alpha(2)-606 
subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. 607 
Eur J Neurosci 13:428-442. 608 
Panzanelli P, Gunn BG, Schlatter MC, Benke D, Tyagarajan SK, Scheiffele P, Belelli D, 609 
Lambert JJ, Rudolph U, Fritschy JM (2011) Distinct mechanisms regulate GABAA receptor 610 
and gephyrin clustering at perisomatic and axo-axonic synapses on CA1 pyramidal cells. J 611 
Physiol 589:4959-4980. 612 
Poulopoulos A, Aramuni G, Meyer G, Soykan T, Hoon M, Papadopoulos T, Zhang M, 613 
Paarmann I, Fuchs C, Harvey K, Jedlicka P, Schwarzacher SW, Betz H, Harvey RJ, Brose N, 614 
Zhang W, Varoqueaux F (2009) Neuroligin 2 drives postsynaptic assembly at perisomatic 615 
inhibitory synapses through gephyrin and collybistin. Neuron 63:628-642. 616 
Reissner C, Stahn J, Breuer D, Klose M, Pohlentz G, Mormann M, Missler M (2014) 617 
Dystroglycan binding to alpha-neurexin competes with neurexophilin-1 and neuroligin in the 618 
brain. J Biol Chem 289:27585-27603. 619 
Satz JS, Ostendorf AP, Hou S, Turner A, Kusano H, Lee JC, Turk R, Nguyen H, Ross-Barta 620 
SE, Westra S, Hoshi T, Moore SA, Campbell KP (2010) Distinct functions of glial and 621 
neuronal dystroglycan in the developing and adult mouse brain. J Neurosci 30:14560-14572. 622 
Schafer MK, Varoqui H, Defamie N, Weihe E, Erickson JD (2002) Molecular cloning and 623 
functional identification of mouse vesicular glutamate transporter 3 and its expression in 624 
subsets of novel excitatory neurons. J Biol Chem 277:50734-50748. 625 
Sugita S, Saito F, Tang J, Satz J, Campbell K, Sudhof TC (2001) A stoichiometric complex of 626 
neurexins and dystroglycan in brain. J Cell Biol 154:435-445. 627 
Sumita K, Sato Y, Iida J, Kawata A, Hamano M, Hirabayashi S, Ohno K, Peles E, Hata Y 628 
(2007) Synaptic scaffolding molecule (S-SCAM) membrane-associated guanylate kinase with 629 
24 
 
inverted organization (MAGI)-2 is associated with cell adhesion molecules at inhibitory 630 
synapses in rat hippocampal neurons. J Neurochem 100:154-166. 631 
Tyagarajan SK, Fritschy JM (2014) Gephyrin: a master regulator of neuronal function? Nat 632 
Rev Neurosci 15:141-156. 633 
Vaillend C, Perronnet C, Ros C, Gruszczynski C, Goyenvalle A, Laroche S, Danos O, Garcia 634 
L, Peltekian E (2010) Rescue of a dystrophin-like protein by exon skipping in vivo restores 635 
GABAA-receptor clustering in the hippocampus of the mdx mouse. Mol Ther 18:1683-1688. 636 
Waite A, Brown SC, Blake DJ (2012) The dystrophin-glycoprotein complex in brain 637 
development and disease. Trends Neurosci 35:487-496. 638 
Wright KM, Lyon KA, Leung H, Leahy DJ, Ma L, Ginty DD (2012) Dystroglycan organizes 639 
axon guidance cue localization and axonal pathfinding. Neuron 76:931-944. 640 
Wyeth MS, Zhang N, Mody I, Houser CR (2010) Selective reduction of cholecystokinin-641 
positive basket cell innervation in a model of temporal lobe epilepsy. J Neurosci 30:8993-642 
9006. 643 
Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, 644 
Shimizu T, Matsumura K (2001) Processing of beta-dystroglycan by matrix metalloproteinase 645 
disrupts the link between the extracellular matrix and cell membrane via the dystroglycan 646 
complex. Hum Mol Genet 10:1563-1569. 647 
 648 
Legends 649 
Figure 1. Characterization of NEX-Cre / Dag1 conditional KO mice. A, Representative 650 
examples of NEX-CreTg/+ / Dag1loxP/+ (control) and NEX-CreTg/+ / Dag1loxP/loxP (cKO) mice (4 651 
months of age, siblings, both female). B, cKO mice exhibit reduced body weight compared to 652 
sibling control mice. C, Wet brain weight was lower in cKO mice than in controls. D, cKO 653 
mice exhibited a higher mortality rate than control mice, resulting in a frequency of cKO mice 654 
lower than the expected 25% at the age of 10 weeks. E, Similar levels of α-DG isolated from 655 
cheek muscle were found for cKO and control mice. F, Cre expression was restricted to 656 
pyramidal cells in the hippocampus of cKO and control mice. In adult mice, dentate gyrus 657 
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granule cells were not immunoreactive for Cre recombinase. NeuN and DAPI labeling show 658 
intact neuronal migration when NEX-Cre is used as driver line to ablate Dag1. G, In primary 659 
somatosensory cortex Cre expression was also restricted to pyramidal cells. No migratory 660 
deficits were found in the neocortex in cKO mice. ***p<0.001. 661 
Figure 2. NEX-Cre-mediated ablation of dystroglycan leads to specific loss of dystrophin 662 
glycoprotein complex in pyramidal cells. A, Characteristic staining of α- and β-DG and 663 
dystrophin around CA1 pyramidal layer is lost in cKO mice. Labeling of β-DG and dystrophin 664 
in astrocyte end-feet is retained in cKO mice (asterisks). B, In primary somatosensory cortex 665 
layer 2/3, clustered labeling of DGC components around pyramidal cells is replaced by 666 
diffuse staining in the neuropil. Astrocyte end-feet labeling of β-DG and dystrophin is retained 667 
in cKO mice (asterisks). C, α-DG immunofluorescence in dentate gyrus is unaffected by 668 
NEX-Cre-mediated ablation of DG. D, α-DG expression in striatum is unaffected in cKO 669 
mice, confirming specificity of NEX-Cre expression to pyramidal cells. SR, stratum radiatum; 670 
SP, stratum pyramidale; ML, molecular layer; GCL, granule cell layer. 671 
Figure 3. Loss of neuronal dystroglycan does not prohibit formation of GABAergic PSD but 672 
leads to minor changes in GABAAR subunit clustering. A-C, Triple immunofluorescence 673 
labeling of GABAergic postsynaptic markers in pyramidal layer of hippocampus CA1 area. 674 
The DGC is largely colocalized with α2 subunit and VGAT (A; arrowheads) but also with α1 675 
subunit and NL2 (B; arrowheads). A minority of DGC clusters is not associated with 676 
GABAergic markers (A and B; arrows). D-H, Quantification of postsynaptic GABAergic 677 
markers in CA1 pyramidal cell layer. Cluster density and size are shown for GABAAR α1 (D), 678 
α2 (F) and γ2 (H) subunits and for gephyrin (E) and NL2 (G). A decrease of α1 subunit 679 
cluster size was accompanied by an increased α2 subunit cluster density. I, Colocalization of 680 
postsynaptic GABAergic markers was analyzed in cKO and control mice. Data represent the 681 
number of colocalized clusters as percentage of first mentioned marker. No significant 682 
differences in colocalization were found between genotypes. J, Clustering of synArfGEF was 683 
analyzed in CA1 pyramidal layer of DG cKO and control mice. Data points represent 684 
individual mice. **p<0.01, ***p<0.001 (see Table 2 for statistical tests). 685 
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Figure 4. Neuronal dystroglycan ablation leads to specific loss of terminals from CCK-686 
positive basket cells on hippocampal pyramidal cells. A-D, Triple immunofluorescence 687 
labeling of presynaptic GABAergic markers in hippocampus CA1 area. A, In pyramidal layer, 688 
markers labeling CCK-positive basket cell terminals (CCK8, VGluT3) are missing around 689 
pyramidal cell bodies, but are still present on CCK-positive cell somata occasionally 690 
observed near the pyramidal layer (arrows). These VGluT3-positive boutons on CCK-positive 691 
somata were often immunopositive for synaptotagmin 2. In the pyramidal layer, 692 
immunostaining for synaptotagmin 2 remained in cKO mice. B1 and B2 show separated 693 
channels of insets in A. C, PV immunolabeling in CA1 pyramidal layer of DG cKO mice is 694 
indistinguishable from control. In CA1 pyramidal layer of control mice, the majority of α-DG 695 
clusters is either apposed to VGluT3 (arrow 1) or PV (arrow 2), but some clusters are not 696 
apposed to either marker (arrow 3). A minority of α-DG clusters showed apposition to both 697 
VGluT3 and PV (arrow 4). D, Along with CCK8 and VGluT3, CB1 staining is strongly reduced 698 
in CA1 pyramidal layer of DG cKO mice. E, Loss of CB1 immunofluorescence in DG cKO 699 
mice was observed from CA1 to CA3. F-K, Quantification of presynaptic GABAergic markers 700 
in CA1 pyramidal layer. No changes were found for VGAT (F) and PV-positive basket cell 701 
markers (H, J) between genotypes but cluster density and size of markers of CCK-positive 702 
basket cell terminals (G, I, K) were strongly reduced in DG cKO mice. Data points represent 703 
individual mice. ***p<0.001 (see Table 2 for statistical tests). SR, stratum radiatum; SP, 704 
stratum pyramidale. 705 
Figure 5. Neuronal dystroglycan ablation leads to specific loss of terminals from CCK-706 
positive basket cells on pyramidal cells in neocortex. A-C, Triple immunofluorescence 707 
labeling of GABAergic markers in layer 2/3 of primary somatosensory cortex (S1) of DG cKO 708 
and control mice. A, As in hippocampus, the majority of DG clusters is colocalized with pre- 709 
and postsynaptic GABAergic markers in neocortex. B, Neocortical PV and VGluT3 710 
immunolabeling is not affected by loss of neuronal DG. C, CCK8 and CB1 711 
immunofluorescence is strongly reduced in neocortex of DG cKO mice. Immunolabeling of 712 
synArfGEF showed clustered distribution and did not differ between genotypes. D, Overview 713 
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of S1 of DG cKO and control mice. Typical punctate CB1 immunofluorescence was lost 714 
across all layers of the cortex in DG cKO mice. E-I, Quantification of presynaptic GABAergic 715 
markers in S1 layer 2/3. VGAT and PV, and in contrast to hippocampus, also VGluT3 were 716 
not reduced in density and size in mice lacking neuronal DG (E, F, G). However, CB1 and 717 
CCK8 showed a similar reduction as in hippocampus in DG cKO mice compared to control 718 
mice (H and I). Data points represent individual mice. **p<0.01, ***p<0.001 (see Table 2 for 719 
statistical tests). 720 
Figure 6. Neuronal dystroglycan is not necessary for clustering of glutamatergic synaptic 721 
proteins. A and B, To assess integrity of glutamatergic postsynaptic structures, antibodies to 722 
PSD-95 and bassoon were used and immunofluorescence quantified in stratum pyramidale 723 
and stratum radiatum. Cluster density and size was analyzed in stratum pyramidale and 724 
fluorescence intensity in stratum radiatum. All parameters analyzed did not differ between 725 
genotypes. C, VGluT1 was used as a marker of glutamatergic presynaptic terminals and 726 
puncta density and size in stratum pyramidale was quantified. No changes in VGluT1 puncta 727 
density and size were found between genotypes. D, PSD-95 apposition to VGluT1 was 728 
examined in stratum pyramidale and represented as percent PSD-95 clusters apposed to 729 
VGluT1 puncta. The apposition of PSD-95 to VGluT1 did not differ between genotypes. Data 730 
points represent individual mice. *p<0.05, ***p<0.001 (see Table 2 for statistical tests). 731 
Figure 7. CCK-positive terminals are not established in the absence of neuronal 732 
dystroglycan. A, Triple immunofluorescence labeling of DG cKO and control CA1 pyramidal 733 
layer at postnatal day 21. B and C, Quantification of puncta density and size reveals loss of 734 
VGluT3 puncta in DG cKO tissue to the same degree as in adult mice (B) but unchanged PV 735 
immunolabeling (C). Data points represent individual mice. ***p<0.001 (see Table 2 for 736 
statistical tests). 737 
Figure 8. Maintenance of CCK-positive basket terminals requires dystroglycan. A, Overview 738 
of experimental design. Virus was stereotactically injected unilaterally into CA1 region in 739 
adult mice heterozygous or homozygous for loxP sites flanking Dag1 gene. B, After 14 dpi, 740 
Cre recombinase immunolabeling as well as mCherry fluorescence was clearly visible in 741 
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pyramidal cell somata. C, Example of injection site at 28 dpi. Cre expression was mostly 742 
restricted to CA1 pyramidal cell layer. VGluT3 and dystrophin or DG immunofluorescence 743 
was analyzed in the same sections. D, In mice containing homozygously floxed Dag1, β-DG 744 
immunostaining was markedly reduced in CA1 pyramidal layer at 28 dpi. Heterozygous mice 745 
showed a moderate reduction in β-DG immunofluorescence. E-G, As observed for β-DG, Cre 746 
expression lead to loss of dystrophin in homozygously floxed mice whereas only a slight 747 
decrease was observed in heterzygous mice. Reduction of dystrophin labeling was similar at 748 
28 dpi (E), 42 dpi (F) and 84 dpi (G). H-J, Representative example images and 749 
quantifications of VGluT3 immunostaining in CA1 pyramidal layer at 28 dpi (H), 42 dpi (I) and 750 
84 dpi (J). Ipsilateral VGluT3 size and density in homozygously floxed mice was significantly 751 
reduced compared to both contralateral side and ipsilateral side of heterozygously floxed 752 
mice. With increased time after injection this reduction of VGluT3 puncta became more 753 
prominent. Data points represent individual mice. *p<0.05, **p<0.01, ***p<0.001 (see Table 2 754 
for statistical tests). 755 
Figure 9. Frequency and amplitude of sIPSCs are reduced in dystroglycan cKO pyramidal 756 
cells. A, Image showing the position of the recording pipette in the hippocampal CA1 region 757 
(left, 4x), and an example image of a typical CA1 pyramidal cell identified using LED 758 
illumination (Alexa Fluor 488, right, 40x). B, Representative example traces of whole-cell 759 
sIPSC recordings from control mice (left trace) and DG cKO mice (right trace). Average 760 
sIPSCs are shown above the traces. C, Cumulative frequency plot of inter-event intervals of 761 
sIPSCs from control (blue line) and DG cKO cell (red line) from the traces in B (left panel) 762 
and cumulative frequency plot of sIPSC amplitudes from the same cells (right panel). D, 763 
Comparison of average sIPSC frequency and amplitude between control and DG cKO slices. 764 
DG cKO mice exhibit significantly lower sIPSC frequency and amplitude than control mice. 765 
Data points represent individual cells. *p<0.05. 766 
Figure 10. Dystroglycan is necessary for carbachol-induced increase of inhibitory currents in 767 
pyramidal cells.  A, Representative example traces of sIPSC recordings before (baseline, left 768 
trace) and after the application of carbachol (CCh, right trace) in control mice. Average 769 
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sIPSCs are shown above the traces. B, Cumulative frequency plots of inter-event intervals 770 
(IEI) and amplitudes of sIPSCs from traces in A. C, Comparison of average sIPSC frequency 771 
and amplitude before and after application of CCh in control slices. Application of CCh 772 
resulted in typical increase of IPSC frequency in control pyramidal cells but amplitude was 773 
not affected by CCh. D, Representative example traces of sIPSC recordings before 774 
(baseline, left trace) and after the application of CCh (right trace) in DG cKO mice. Average 775 
sIPSCs are shown above the traces. E, Cumulative frequency plots of inter-event intervals 776 
(IEI) and amplitudes of sIPCSs from traces in D. F, Comparison of average sIPSC frequency 777 
and amplitude before and after application of CCh in DG cKO slices. In contrast to control 778 
slices, application of CCh did not lead to a significant increase of sIPSC frequency in DG 779 
cKO pyramidal cells. Data points represent individual cells. **p<0.01. 780 
Figure 11. Neurexin- and laminin-binding of α-dystroglycan is not essential for formation of 781 
CCK-positive basket terminals on pyramidal cells. A and B, Triple immunofluorescence 782 
labeling of GABAergic markers in CA1 pyramidal layer of Dag1 T190M and wildtype mice. A, 783 
Antibody to β-DG revealed typical clustered distribution in Dag1 T190M mice. VGluT3 and 784 
PV immunofluorescence was indistinguishable between genotypes. B, Intensity of DG 785 
clusters was markedly reduced and background staining increased using the α-DG 786 
glycosylation-specific antibody 11H6, confirming glycosylation deficits of synaptic DG in 787 
T190M mice. CB1 and GABAAR γ2 subunit immunofluorescence was indistinguishable 788 
between genotypes. C and D, Quantification of density and size of VGluT3 (C) and CB1 (D) 789 
puncta in CA1 pyramidal layer of Dag1 T190M and wildtype mice. Density and size of puncta 790 
did not differ significantly between genotypes. E, Quantification of β-DG apposition to PV 791 
and/or VGluT3 in CA1 pyramidal layer. Data represent number of β-DG clusters apposed to 792 
PV or VGluT3 or both (triple colocalized) as percentage of total β-DG clusters. Apposition of 793 
β-DG to presynaptic markers did not differ significantly between genotypes. Data points 794 
represent individual mice. See Table 2 for statistical tests. 795 
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Illustrations and Tables 796 
Table 1. Antibodies used for immunohistochemical stainings 797 
Target Host species Dilution Cat. no. Company / origin 
α-Dystroglycan (VIA4-1) Mouse 1:100 05-298 EMD Millipore 
α-Dystroglycan (11H6C4) Mouse 1:100 05-593 EMD Millipore 
β-Dystroglycan Mouse 1:100 ab49515 Abcam 
Bassoon Mouse 1:2000 VAM-PS003 StressGen 
Cannabinoid receptor 1 Rabbit 1:3000 258 003 Synaptic Systems 
Cholecystokinin 8 Mouse 1:1000 ab37274 Abcam 
Cre recombinase Rabbit 1:1000 PRB-106C Covance 
Dystrophin (C-terminal) Mouse 1:100 BT39-9050-05 Biotrend 
GABAAR α1 subunit Guinea pig 1:20‘000 - (Fritschy and Mohler, 1995) 
GABAAR α2 subunit Guinea pig 1:6000 - (Fritschy and Mohler, 1995) 
GABAAR γ2 subunit Guinea pig 1:10‘000 - (Fritschy and Mohler, 1995) 
GAD65/67 Rabbit 1:2000 GC 3008 Biomol 
Gephyrin Mouse 1:1000 147 021 Synaptic Systems 
NeuN Mouse 1:1000 MAB377 Chemicon 
Neuroligin 2 Rabbit 1:10‘000 - Gift from Dr. Peter Scheiffele 
Parvalbumin Rabbit 1:1000 24428 ImmunoStar 
PSD-95 Mouse 1:1000 MA1-045 ABR 
Synaptotagmin 2 Rabbit 1:1000 105 123 Synaptic Systems 
synArfGEF Guinea pig 1:3000 - Gift from Dr. Hiroyuki Sakagami 
(Fukaya et al., 2011) 
VGAT Rabbit 1:3000 131 003 Synaptic Systems 
VGluT1 Guinea pig 1:1000 135 304 Synaptic Systems 
VGluT3 Guinea pig 1:4000 AB5421 Merck Millipore 
 798 
Table 1. Antibodies used for immunohistochemical stainings. If not otherwise stated, 799 
antibody VIA4-1 was used to label α-dystroglycan. For secondary antibodies see Materials 800 
and Methods. 801 
 802 
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Table 2. Results of statistical tests performed for immunohistochemical stainings 803 
 
Epitope 
 
Conditions 
Unpaired t-test 
(density) 
 
Kolmogorov-Smirnov test (size) 
GABAAR α1 subunit DG cKO / adult / CA1 t6=0.920, p=0.393 n=33385, D=12.662, p<0.001 
GABAAR α2 subunit DG cKO / adult / CA1 t15=3.816, p=0.002 n=18495, D=3.484, p<0.001 
GABAAR γ2 subunit DG cKO / adult / CA1 t7=1.607, p=0.152 n=31807, D=3.692, p<0.001 
Gephyrin DG cKO / adult / CA1 t7=1.252, p=0.251 n=39289, D=0.720, p=0.677 
Neuroligin 2 DG cKO / adult / CA1 t6=0.979, p=0.366 n=32217, D=5.476, p<0.001 
synArfGEF DG cKO / adult / CA1 t6=1.093, p=0.316 n=22737, D=3.850, p<0.001 
VGAT DG cKO / adult / CA1 t15=0.646, p=0.528 n=20569, D=0.528, p=0.943 
 DG cKO / adult / neocortex t9=1.309, p=0.223 n=24713, D=1.107, p=0.172 
Parvalbumin DG cKO / adult / CA1 t7=0.198, p=0.849 n=24929, D=1.068, p=0.204 
 DG cKO / adult / neocortex t9=0.454, p=0.661 n=20534, D=4.845, p<0.001 
 DG cKO / P21 / CA1 t8=0.869, p=0.410 n=8010, D=1.037, p=0.233 
Cannabinoid DG cKO / adult / CA1 t6=16.869, p<0.001 n=4654, D=4.325, p<0.001 
receptor 1 DG cKO / adult / neocortex t11=7.117, p<0.001 n=8067, D=6.960, p<0.001 
 T190M / adult / CA1 t8=0.681, p=0.515 n=9152, D=0.881, p=0.420 
Synaptotagmin 2 DG cKO / adult / CA1 t9=1.456, p=0.179 n=3397, D=1.977, p=0.001 
Cholecystokinin 8 DG cKO / adult / CA1 t17=6.292, p<0.001 n=5111, D=4.133, p<0.001 
 DG cKO / adult / neocortex t6=4.475, p=0.004 n=1387, D=1.874, p=0.002 
PSD-95 DG cKO / adult / CA1 / SP t6=1.106, p=0.311 n=16281, D=1.554, p=0.016 
 DG cKO / adult / CA1 / SR t6=0.243, p=0.817 - 
Bassoon DG cKO / adult / CA1 / SP t10=0.767, p=0.461 n=32489, D=2.275, p<0.001 
 DG cKO / adult / CA1 / SR t10=0.871, p=0.404 - 
VGluT1 DG cKO / adult / CA1 t6=0.094, p=0.928 n=12776, D=0.492, p=0.969 
VGluT3 DG cKO / adult / CA1 t21=13.213, p<0.001 n=5975, D=8.273, p<0.001 
 DG cKO / adult / neocortex t9=0.456, p=0.659 n=6523, D=2.054, p<0.001 
 DG cKO / P21 / CA1 t8=13.437, p<0.001 n=1830, D=8.270, p<0.001 
 T190M / adult / CA1 t8=0.494, p=0.634 n=4763, D=0.702, p=0.708 
  
 
 
 
 
t-test (unpaired 
between genotypes, 
paired between 
 
 
 
Kruskal-
 
 
 
Dunn’s multiple 
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Conditions 
hemispheres; 
density) 
Wallis test 
(size) 
comparison test 
(size) 
 28dpi / loxP/+ t3=0.520, p=0.639 n=13610 y=283.498, p<0.05 
 28dpi / loxP/loxP t4=2.895, p=0.044 H=55.796 y=539.294, p<0.001 
 28dpi / contralateral t7=1.032, p=0.336 p<0.001 y=136.188, p>0.05 
 28dpi / ipsilateral t7=2.894, p=0.023  y=391.984, p<0.001 
 42dpi / loxP/+ t4=0.870, p=0.434 n=9915 y=93.906, p>0.05 
 42dpi / loxP/loxP t4=3.478, p=0.025 H=87.162 y=693.091, p<0.001 
 42dpi / contralateral t8=1.040, p=0.329 p<0.001 y=82.049, p>0.05 
 42dpi / ipsilateral t8=4.059, p=0.004  y=681.234, p<0.001 
 84dpi / loxP/+ t5=1.843, p=0.125 n=7378 y=16.550, p>0.05 
 84dpi / loxP/loxP t3=8.578, p=0.003 H=52.415 y=466.868, p<0.001 
 84dpi / contralateral t8=0.682, p=0.515 P<0.001 y=143.428, p>0.05 
 84dpi / ipsilateral t8=3.495, p=0.008  y=593.745, p<0.001 
 804 
Table 2. Results of statistical tests performed for immunohistochemical stainings. Numbers in 805 
subscript in t-tests represent degrees of freedom. D, H and y represent test statistics for 806 
Kolmogorov-Smirnov tests, Kruskal-Wallis tests and Dunn’s multiple comparison tests, 807 
respectively. 808 
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